1-2 of 2
Guy Pratt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B020: SF3B1 hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response

Philip Bland, Harry Saville, Patty T Wai, Lucinda Curnow, Jadwiga Nieminuszczy, Nivedita Ravindran, Holly E Barker, James Wright, Lu Yu, Ioanna Mavrommati, Barrie Peck, Patrycja Gazinska, Helen N Pemberton, Aditi Gulati, Naomi Guppy, Ioannis Roxanis, Guy Pratt, Ceri Oldreive, Tatjana Stankovic, Samantha Barlow, Helen Kalirai, Sarah E Coupland, Ronan Broderick, Samar Alsafadi, Alexandre Houy, Marc-Henri Stern, Stephen Pettit, Jyoti S Choudhary, Syed Haider, Wojciech Niedzwiedz, Christopher J Lord, Rachael Natrajan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B020.
https://doi.org/10.1158/1535-7163.TARG-23-B020
Published: 01 December 2023
View article titled, Abstract B020: <em>SF3B1 </em>hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response
Journal Articles

The NF-κB Inhibitor LC-1 Has Single Agent Activity in Multiple Myeloma Cells and Synergizes with Bortezomib

Elisabeth J. Walsby, Guy Pratt, Saman Hewamana, Peter A. Crooks, Alan K. Burnett, Chris Fegan, Chris Pepper
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1574–1582.
https://doi.org/10.1158/1535-7163.MCT-10-0104
Published: 09 June 2010
View article titled, The NF-κB Inhibitor LC-1 Has Single Agent Activity in Multiple Myeloma Cells and Synergizes with Bortezomib
Open the PDF for The NF-κB Inhibitor LC-1 Has Single Agent Activity in Multiple Myeloma Cells and Synergizes with Bortezomib in another window